Discussing New Phase 2 Findings on Lutikizumab for Hidradenitis Suppurativa with Alexa Kimball, MD, MPH

Kimball discusses her team’s new late-breaking data regarding the safety and effectiveness of lutikizumab in treating the symptoms of moderate-to-severe HS in adult non-responders to anti-TNF therapy.

Related Keywords

Massachusetts ,United States ,American ,Alexa Kimball ,Harvard Medical School ,American Academy Of Dermatology ,Annual Meeting ,Hidradenitis Suppurativa Clinical Response ,Massachusetts General Hospital ,Numeric Rating Scale ,Global Assessment ,Dhs ,Hidradenitis Suppurativa ,Lutikizumab ,Anti Tnf ,Interleukin ,Phase 2 ,Aad ,Late Breaking ,